Aptose Biosciences Inc. (NASDAQ:APTO) has been given a consensus rating of “Buy” by the six ratings firms that are presently covering the company. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.67.
A number of equities analysts have recently weighed in on APTO shares. RBC Capital Markets reiterated an “outperform” rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $23.00 price target on shares of Aptose Biosciences in a report on Saturday, June 25th. Roth Capital reiterated a “buy” rating and set a $8.00 price target on shares of Aptose Biosciences in a report on Friday. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 11th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Saturday.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences as of its most recent filing with the SEC. 19.47% of the stock is currently owned by institutional investors.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down 7.3409% during midday trading on Tuesday, hitting $2.0385. The stock had a trading volume of 67,934 shares. Aptose Biosciences has a one year low of $1.92 and a one year high of $6.40. The firm has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.46. The stock’s market cap is $26.28 million.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.